Search

Your search keyword '"Bröckelmann, Paul J."' showing total 273 results
Start Over Author "Bröckelmann, Paul J."
273 results on '"Bröckelmann, Paul J."'

51. Grade 4 Neutropenia Secondary to Immune Checkpoint Inhibition — A Descriptive Observational Retrospective Multicenter Analysis

Author

Zaremba, Anne, primary, Kramer, Rafaela, additional, De Temple, Viola, additional, Bertram, Stefanie, additional, Salzmann, Martin, additional, Gesierich, Anja, additional, Reinhardt, Lydia, additional, Baroudjian, Barouyr, additional, Sachse, Michael M., additional, Mechtersheimer, Gunhild, additional, Johnson, Douglas B., additional, Weppler, Alison M., additional, Spain, Lavinia, additional, Loquai, Carmen, additional, Dudda, Milena, additional, Pföhler, Claudia, additional, Hepner, Adriana, additional, Long, Georgina V., additional, Menzies, Alexander M., additional, Carlino, Matteo S., additional, Lebbé, Céleste, additional, Enokida, Tomohiro, additional, Tahara, Makoto, additional, Bröckelmann, Paul J., additional, Eigentler, Thomas, additional, Kähler, Katharina C., additional, Gutzmer, Ralf, additional, Berking, Carola, additional, Ugurel, Selma, additional, Stadtler, Nadine, additional, Sucker, Antje, additional, Becker, Jürgen C., additional, Livingstone, Elisabeth, additional, Meier, Friedegund, additional, Hassel, Jessica C., additional, Schadendorf, Dirk, additional, Hanoun, Maher, additional, Heinzerling, Lucie, additional, and Zimmer, Lisa, additional

Published
2021
Full Text
View/download PDF

53. Clinical outcomes of relapsed and refractory Hodgkin lymphoma patients after contemporary first-line treatment: a German Hodgkin Study Group analysis

Author

Bröckelmann, Paul J., primary, Müller, Horst, additional, Gillessen, Sarah, additional, Yang, Xiaoqin, additional, Koeppel, Larissa, additional, Pilz, Veronika, additional, Marinello, Patricia, additional, Kaskel, Peter, additional, Raut, Monika, additional, Fuchs, Michael, additional, Borchmann, Peter, additional, Engert, Andreas, additional, and von Tresckow, Bastian, additional

Published
2021
Full Text
View/download PDF

54. Impact of centralized diagnostic review on quality of initial staging in Hodgkin lymphoma: experience of the German Hodgkin Study Group

Author

Bröckelmann, Paul J., Goergen, Helen, Fuchs, Michael, Kriz, Jan, Semrau, Robert, Baues, Christian, Kobe, Carsten, Behringer, Karolin, Eichenauer, Dennis A., von Tresckow, Bastian, Klimm, Beate, Halbsguth, Teresa, Wongso, Diana, Plütschow, Annette, Haverkamp, Heinz, Dietlein, Markus, Eich, Hans T., Stein, Harald, Diehl, Volker, Borchmann, Peter, and Engert, Andreas

Published
2015
Full Text
View/download PDF

55. Reverted exhaustion phenotype of circulating lymphocytes as immune correlate of anti-PD1 first-line treatment in Hodgkin lymphoma

Author

Garcia-Marquez, Maria A., primary, Thelen, Martin, additional, Reinke, Sarah, additional, Keller, Diandra, additional, Wennhold, Kerstin, additional, Lehmann, Jonas, additional, Veldman, Johanna, additional, Borchmann, Sven, additional, Rosenwald, Andreas, additional, Sasse, Stephanie, additional, Diepstra, Arjan, additional, Borchmann, Peter, additional, Engert, Andreas, additional, Klapper, Wolfram, additional, von Bergwelt-Baildon, Michael, additional, Bröckelmann, Paul J., additional, and Schlößer, Hans A., additional

Published
2021
Full Text
View/download PDF

56. 9p24.1 alterations and programmed cell death 1 ligand 1 expression in early stage unfavourable classical Hodgkin lymphoma: an analysis from the German Hodgkin Study Group NIVAHL trial

Author

Gerhard‐Hartmann, Elena, primary, Goergen, Helen, additional, Bröckelmann, Paul J., additional, Mottok, Anja, additional, Steinmüller, Tabea, additional, Grund, Johanna, additional, Zamò, Alberto, additional, Ben‐Neriah, Susana, additional, Sasse, Stephanie, additional, Borchmann, Sven, additional, Fuchs, Michael, additional, Borchmann, Peter, additional, Reinke, Sarah, additional, Engert, Andreas, additional, Veldman, Johanna, additional, Diepstra, Arjan, additional, Klapper, Wolfram, additional, and Rosenwald, Andreas, additional

Published
2021
Full Text
View/download PDF

57. Treatment patterns and disease course of previously untreated Primary Central Nervous System Lymphoma: Feasibility of MTX‐based regimens in clinical routine

Author

Sieg, Noëlle, primary, Naendrup, Jan‐Hendrik, additional, Gödel, Philipp, additional, Balke‐Want, Hyatt, additional, Simon, Florian, additional, Deckert, Martina, additional, Gillessen, Sarah, additional, Kreissl, Stefanie, additional, Bröckelmann, Paul J., additional, Borchmann, Peter, additional, Tresckow, Bastian, additional, and Heger, Jan‐Michel, additional

Published
2021
Full Text
View/download PDF

58. Hematological immune related adverse events after treatment with immune checkpoint inhibitors

Author

Kramer, Rafaela, primary, Zaremba, Anne, additional, Moreira, Alvaro, additional, Ugurel, Selma, additional, Johnson, Douglas B., additional, Hassel, Jessica C., additional, Salzmann, Martin, additional, Gesierich, Anja, additional, Weppler, Alison, additional, Spain, Lavinia, additional, Loquai, Carmen, additional, Dudda, Milena, additional, Pföhler, Claudia, additional, Hepner, Adriana, additional, Long, Georgina V., additional, Menzies, Alexander M., additional, Carlino, Matteo S., additional, Sachse, Michael M., additional, Lebbé, Céleste, additional, Baroudjian, Barouyr, additional, Enokida, Tomohiro, additional, Tahara, Makoto, additional, Schlaak, Max, additional, Hayani, Kinan, additional, Bröckelmann, Paul J., additional, Meier, Friedegund, additional, Reinhardt, Lydia, additional, Friedlander, Philip, additional, Eigentler, Thomas, additional, Kähler, Katharina C., additional, Berking, Carola, additional, Zimmer, Lisa, additional, and Heinzerling, Lucie, additional

Published
2021
Full Text
View/download PDF

59. Exhaustive circulating tumor DNA sequencing reveals the genomic landscape of Hodgkin lymphoma and facilitates ultrasensitive detection of minimal residual disease

Author

Sobesky, Sophia, primary, Mammadova, Laman, additional, Cirillo, Melita, additional, Drees, Esther, additional, Mattlener, Julia, additional, Dörr, Helge, additional, Altmüller, Janine, additional, Shi, Zhiyuan, additional, Bröckelmann, Paul J, additional, Weiss, Jonathan, additional, Kreissl, Stefanie, additional, Sasse, Stephanie, additional, Ullrich, Roland T, additional, Reinke, Sarah, additional, Klapper, Wolfram, additional, Gerhard-Hartmann, Elena, additional, Rosenwald, Andreas, additional, Roemer, Margaretha GM, additional, Nürnberg, Peter, additional, Hagenbeek, Anton, additional, Zijlstra, Josée M., additional, Pegtel, Dirk Michiel, additional, Engert, Andreas, additional, Borchmann, Peter, additional, von Tresckow, Bastian, additional, and Borchmann, Sven, additional

Published
2021
Full Text
View/download PDF

60. Early Response to First-Line Anti–PD-1 Treatment in Hodgkin Lymphoma: A PET-Based Analysis from the Prospective, Randomized Phase II NIVAHL Trial

Author

Voltin, Conrad-Amadeus, primary, Mettler, Jasmin, additional, van Heek, Lutz, additional, Goergen, Helen, additional, Müller, Horst, additional, Baues, Christian, additional, Keller, Ulrich, additional, Meissner, Julia, additional, Trautmann-Grill, Karolin, additional, Kerkhoff, Andrea, additional, Fuchs, Michael, additional, Sasse, Stephanie, additional, von Tresckow, Bastian, additional, Dietlein, Markus, additional, Borchmann, Peter, additional, Engert, Andreas, additional, Kobe, Carsten, additional, and Bröckelmann, Paul J., additional

Published
2021
Full Text
View/download PDF

61. Relapse After Early-Stage, Favorable Hodgkin Lymphoma: Disease Characteristics and Outcomes With Conventional or High-Dose Chemotherapy

Author

Bröckelmann, Paul J., primary, Müller, Horst, additional, Guhl, Teresa, additional, Behringer, Karolin, additional, Fuchs, Michael, additional, Moccia, Alden A., additional, Rank, Andreas, additional, Soekler, Martin, additional, Vieler, Tom, additional, Pabst, Thomas, additional, Baues, Christian, additional, von Tresckow, Bastian, additional, Borchmann, Peter, additional, and Engert, Andreas, additional

Published
2021
Full Text
View/download PDF

63. Efficacy and Safety of Nivolumab and AVD in Early-Stage Unfavorable Hodgkin Lymphoma: Extended Follow-up from the GHSG Phase II Nivahl Trial

Author

Bröckelmann, Paul J, primary, Goergen, Helen, additional, Keller, Ulrich, additional, Meissner, Julia, additional, Trautmann, Karolin, additional, Halbsguth, Teresa V, additional, Sasse, Stephanie, additional, Sökler, Martin, additional, Kerkhoff, Andrea, additional, Mathas, Stephan, additional, Hüttmann, Andreas, additional, Bormann, Matthias, additional, Zimmermann, Andreas, additional, Fuchs, Michael, additional, von Tresckow, Bastian, additional, Baues, Christian, additional, Rosenwald, Andreas, additional, Klapper, Wolfram, additional, Kobe, Carsten, additional, Borchmann, Peter, additional, and Engert, Andreas, additional

Published
2020
Full Text
View/download PDF

65. Reinduction therapy with everolimus in combination with dexamethasone, high‐dose cytarabin and cisplatinum in patients with relapsed or refractory classical Hodgkin lymphoma: an experimental phase I/II multicentre trial of the German Hodgkin Study Group (GHSG HD‐R3i)

Author

Gillessen, Sarah, Hüttmann, Andreas, Vucinic, Vladan, Müller, Horst, Plütschow, Annette, Viardot, Andreas, Topp, Max S., Kobe, Carsten, Böll, Boris, Eichenauer, Dennis A., Sasse, Stephanie, Haverkamp, Heinz, Schmitz, Christine, Borchmann, Sven, Bröckelmann, Paul J., Heger, Jan‐Michel, Fuchs, Michael, Engert, Andreas, Borchmann, Peter, and von Tresckow, Bastian

Subjects
HODGKIN'S disease, EVEROLIMUS, STEM cell transplantation, DEXAMETHASONE, COMPUTED tomography
Abstract

Summary: Reinduction chemotherapy followed by high‐dose chemotherapy and autologous stem cell transplant (HDCT + ASCT) is second‐line standard of care for transplant‐eligible patients with relapsed/refractory classical Hodgkin lymphoma (r/r cHL) but has a high failure rate. Because response to reinduction is predictive of the outcome after HDCT + ASCT, we aimed to improve the standard dexamethasone, high‐dose cytarabine and cisplatinum (DHAP) reinduction regimen by addition of the oral mammalian target of rapamycin inhibitor everolimus (everDHAP). Transplant‐eligible patients aged 18–60 years with histologically confirmed r/r cHL were included in this experimental phase I/II trial. Everolimus (10 mg/day, determined in phase‐I‐part) was administered on day 0–13 of each DHAP cycle. From July 2014 to March 2018, 50 patients were recruited to the phase II everDHAP group; two were not evaluable, three discontinued due to toxicity. Randomization to a placebo group stopped in October 2015 due to poor recruitment after nine patients. The primary end‐point of computed tomography (CT)‐based complete remission (CR) after two cycles of everDHAP was expected to be ≥40%. With a CT‐based CR rate of 27% (n = 12/45) after two cycles of everDHAP the trial did not meet the primary end‐point. Adding everolimus to DHAP is thus feasible; however, the everDHAP regimen failed to show an improved efficacy. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

66. 9p24.1 alterations and programmed cell death 1 ligand 1 expression in early stage unfavourable classical Hodgkin lymphoma: an analysis from the German Hodgkin Study Group NIVAHL trial.

Author

Gerhard‐Hartmann, Elena, Goergen, Helen, Bröckelmann, Paul J., Mottok, Anja, Steinmüller, Tabea, Grund, Johanna, Zamò, Alberto, Ben‐Neriah, Susana, Sasse, Stephanie, Borchmann, Sven, Fuchs, Michael, Borchmann, Peter, Reinke, Sarah, Engert, Andreas, Veldman, Johanna, Diepstra, Arjan, Klapper, Wolfram, and Rosenwald, Andreas

Subjects
PROGRAMMED death-ligand 1, HODGKIN'S disease, MANTLE cell lymphoma, MAJOR histocompatibility complex
Abstract

Summary: High programmed cell death 1 ligand 1 (PD‐L1) protein expression and copy number alterations (CNAs) of the corresponding genomic locus 9p24.1 in Hodgkin‐ and Reed–Sternberg cells (HRSC) have been shown to be associated with favourable response to anti‐PD‐1 checkpoint inhibition in relapsed/refractory (r/r) classical Hodgkin lymphoma (cHL). In the present study, we investigated baseline 9p24.1 status as well as PD‐L1 and major histocompatibility complex (MHC) class I and II protein expression in 82 biopsies from patients with early stage unfavourable cHL treated with anti‐PD‐1‐based first‐line treatment in the German Hodgkin Study Group (GHSG) NIVAHL trial (ClinicalTrials.gov Identifier: NCT03004833). All evaluated specimens showed 9p24.1 CNA in HRSC to some extent, but with high intratumoral heterogeneity and an overall smaller range of alterations than reported in advanced‐stage or r/r cHL. All but two cases (97%) showed PD‐L1 expression by the tumour cells in variable amounts. While MHC‐I was rarely expressed in >50% of HRSC, MHC‐II expression in >50% of HRSC was found more frequently. No obvious impact of 9p24.1 CNA or PD‐L1 and MHC‐I/II expression on early response to the highly effective anti‐PD‐1‐based NIVAHL first‐line treatment was observed. Further studies evaluating an expanded panel of potential biomarkers are needed to optimally stratify anti‐PD‐1 first‐line cHL treatment. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

67. How I treat advanced Hodgkin lymphoma — a global view

Author

Hokland, Peter, primary, Shah, Mansi, additional, David, Kevin, additional, Evens, Andrew, additional, Auer, Rebecca, additional, Ledieu, Rifca, additional, Kreissl, Stefanie, additional, Bröckelmann, Paul J., additional, Borchmann, Peter, additional, Korula, Anu, additional, Mathews, Vikram, additional, Owattanapanich, Weerapat, additional, and Trotman, Judith, additional

Published
2020
Full Text
View/download PDF

69. Efficacy of Nivolumab and AVD in Early-Stage Unfavorable Classic Hodgkin Lymphoma

Author

Bröckelmann, Paul J., primary, Goergen, Helen, additional, Keller, Ulrich, additional, Meissner, Julia, additional, Ordemann, Rainer, additional, Halbsguth, Teresa V., additional, Sasse, Stephanie, additional, Sökler, Martin, additional, Kerkhoff, Andrea, additional, Mathas, Stephan, additional, Hüttmann, Andreas, additional, Bormann, Matthias, additional, Zimmermann, Andreas, additional, Mettler, Jasmin, additional, Fuchs, Michael, additional, von Tresckow, Bastian, additional, Baues, Christian, additional, Rosenwald, Andreas, additional, Klapper, Wolfram, additional, Kobe, Carsten, additional, Borchmann, Peter, additional, and Engert, Andreas, additional

Published
2020
Full Text
View/download PDF

72. Nivolumab and AVD for Early-Stage Unfavorable Hodgkin Lymphoma (NIVAHL)

Author

Bröckelmann, Paul J, primary, Goergen, Helen, primary, Keller, Ulrich, primary, Meissner, Julia, primary, Ordemann, Rainer, primary, Halbsguth, Teresa V, primary, Sasse, Stephanie, primary, Sökler, Martin, primary, Kerkhoff, Andrea, primary, Mathas, Stephan, primary, Hüttmann, Andreas, primary, Bormann, Matthias, primary, Zimmermann, Andreas, primary, Fuchs, Michael, primary, von Tresckow, Bastian, primary, Baues, Christian, primary, Rosenwald, Andreas, primary, Klapper, Wolfram, primary, Kobe, Carsten, primary, Borchmann, Peter, primary, and Engert, Andreas, primary

Published
2019
Full Text
View/download PDF

73. Abscopal Effect of Radiotherapy and Nivolumab in Relapsed or Refractory Hodgkin Lymphoma (AERN): An International Multicenter Single-Arm Two-Stage Phase II GHSG Trial

Author

Bröckelmann, Paul J, primary, Plütschow, Annette, additional, Greil, Richard, additional, Zijlstra, Josée M, additional, Illidge, Timothy, additional, Fosså, Alexander, additional, Meissner, Julia, additional, Zimmermann, Andreas, additional, Mathas, Stephan, additional, Thol, Felicitas, additional, Fuchs, Michael, additional, Engert, Andreas, additional, and Baues, Christian, additional

Published
2019
Full Text
View/download PDF

74. Metabolic Tumor Volume for Early Response Assessment in Early-Stage Unfavorable Hodgkin Lymphoma Treated with Nivolumab in the GHSG Nivahl Phase II Trial

Author

Voltin, Conrad-Amadeus, primary, Mettler, Jasmin, additional, Mueller, Horst, additional, Fuchs, Michael, additional, Baues, Christian, additional, Dietlein, Markus, additional, Engert, Andreas, additional, Borchmann, Peter, additional, Kobe, Carsten, additional, and Bröckelmann, Paul J, additional

Published
2019
Full Text
View/download PDF

83. Patient and physician preferences for first‐line treatment of classical Hodgkin lymphoma in Germany, France and the United Kingdom

Author

Bröckelmann, Paul J., primary, McMullen, Suzanne, additional, Wilson, J Ben, additional, Mueller, Kerstin, additional, Goring, Sarah, additional, Stamatoullas, Aspasia, additional, Zagadailov, Erin, additional, Gautam, Ashish, additional, Huebner, Dirk, additional, Dalal, Mehul, additional, and Illidge, Tim, additional

Published
2018
Full Text
View/download PDF

84. Hodgkin Lymphoma in Adults

Author

Bröckelmann, Paul J., primary, Eichenauer, Dennis A., additional, Jakob, Tina, additional, Follmann, Markus, additional, Engert, Andreas, additional, and Skoetz, Nicole, additional

Published
2018
Full Text
View/download PDF

85. Real-world effectiveness of brentuximab vedotin versus physicians’ choice chemotherapy in patients with relapsed/refractory Hodgkin lymphoma following autologous stem cell transplantation in the United Kingdom and Germany

Author

Zagadailov, Erin A., primary, Corman, Shelby, additional, Chirikov, Viktor, additional, Johnson, Courtney, additional, Macahilig, Cynthia, additional, Seal, Brian, additional, Dalal, Mehul R., additional, Bröckelmann, Paul J., additional, and Illidge, Tim, additional

Published
2017
Full Text
View/download PDF

86. Long-Term Follow-Up of Contemporary Treatment in Early-Stage Hodgkin Lymphoma: Updated Analyses of the German Hodgkin Study Group HD7, HD8, HD10, and HD11 Trials

Author

Sasse, Stephanie, primary, Bröckelmann, Paul J., additional, Goergen, Helen, additional, Plütschow, Annette, additional, Müller, Horst, additional, Kreissl, Stefanie, additional, Buerkle, Carolin, additional, Borchmann, Sven, additional, Fuchs, Michael, additional, Borchmann, Peter, additional, Diehl, Volker, additional, and Engert, Andreas, additional

Published
2017
Full Text
View/download PDF

87. Late Relapse of Classical Hodgkin Lymphoma: An Analysis of the German Hodgkin Study Group HD7 to HD12 Trials

Author

Bröckelmann, Paul J., primary, Goergen, Helen, additional, Kohnhorst, Charlotte, additional, von Tresckow, Bastian, additional, Moccia, Alden, additional, Markova, Jana, additional, Meissner, Julia, additional, Kerkhoff, Andrea, additional, Ludwig, Wolf-Dieter, additional, Fuchs, Michael, additional, Borchmann, Peter, additional, and Engert, Andreas, additional

Published
2017
Full Text
View/download PDF

89. Short review of potential synergies of immune checkpoint inhibition and radiotherapy with a focus on Hodgkin lymphoma: radio-immunotherapy opens new doors

Author

Baues, Christian, primary, Trommer-Nestler, Maike, additional, Jablonska, Karolina, additional, Bröckelmann, Paul J, additional, Schlaak, Max, additional, von Bergwelt-Baildon, Michael, additional, Engert, Andreas, additional, Semrau, Robert, additional, Marnitz, Simone, additional, and Theurich, Sebastian, additional

Published
2017
Full Text
View/download PDF

92. Patient and physician preferences for first‐line treatment of classical Hodgkin lymphoma in Germany, France and the United Kingdom.

Author

Bröckelmann, Paul J., McMullen, Suzanne, Wilson, J Ben, Mueller, Kerstin, Goring, Sarah, Stamatoullas, Aspasia, Zagadailov, Erin, Gautam, Ashish, Huebner, Dirk, Dalal, Mehul, and Illidge, Tim

Subjects
*HODGKIN'S disease, *CANCER treatment, *PHYSICIANS, *LYMPHOMAS, *MEDICAL personnel
Abstract

Summary: First‐line treatments for classical Hodgkin lymphoma (HL) include ABVD (adriamycin, bleomycin, vinblastine, dacarbazine) and BEACOPPescalated (escalated dose bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, prednisone). To further improve overall outcomes, positron emission tomography‐driven strategies and ABVD or BEACOPP variants incorporating the antibody‐drug conjugate brentuximab vedotin (BV) or anti‐PD1 antibodies are under investigation in advanced‐stage patients. The present study aimed to elicit preferences for attributes associated with ABVD, BEACOPPescalated and BV‐AVD (BV, adriamycin, vinblastine and dacarbazine) among patients and physicians. Cross‐sectional online discrete choice experiments were administered to HL patients (n = 381) and haematologists/oncologists (n = 357) in France, Germany and the United Kingdom. Included attributes were progression‐free survival (PFS), overall survival (OS), and the risk of neuropathy, lung damage, infertility and hospitalisation due to adverse events. Whereas 5‐year PFS and OS were the most important treatment attributes to patients, the relative importance of each attribute and preference weights for each level varied among physicians according to the description of the hypothetical patient for whom treatment was recommended. PFS and OS most strongly influenced physicians' recommendations when considering young female patients who did not want children or young male patients. Infertility was more important to physicians' treatment decision than PFS when considering young women with unknown fertility preferences, whereas hospitalisations due to adverse events played the largest role in treatment decisions for older patients. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

93. Fertility and Gonadal Function after First-Line Treatment with Nivolumab-AVD in Hodgkin Lymphoma Patients: An Analysis from the Phase II GHSG Nivahl Trial

Author

Bröckelmann, Paul J, Bühnen, Ina, Herhaus, Peter, Meissner, Julia, Trautmann-Grill, Karolin, Müller, Horst, Fuchs, Michael, von Tresckow, Bastian, Borchmann, Peter, Engert, Andreas, and Behringer, Karolin

Abstract

Background: First-line treatment of patients with classical Hodgkin lymphoma (HL) with anti-PD1 antibodies in combination with AVD chemotherapy is highly effective across risk-groups. Based on encouraging phase II and ongoing phase III trials, anti-PD1 based first-line treatment may hence soon become a first-line treatment option. To date, no data on fertility and gonadal function after anti-PD1 based first-line HL treatment is available. Herein, we present data on pregnancies and gonadal function in patients treated within the randomized GHSG phase II NIVAHL trial.

Published
2023
Full Text
View/download PDF

94. Correlation between Progression-Free Survival and Overall Survival in Patients with Relapsed Hodgkin Lymphoma: An Analysis of Individual Patient Data from Randomized GHSG Trials

Author

Bröckelmann, Paul J, Müller, Horst, Gillessen, Sarah, Jacob, Anne Sophie, Momotow, Jesko, Damaschin, Carla, Ferdinandus, Justin, Yang, Xiaoqin, Fuchs, Michael, Kobe, Carsten, Eich, Hans Theodor, Engert, Andreas, Borchmann, Peter, and von Tresckow, Bastian

Abstract

Background: Progression-free survival (PFS) and overall survival (OS) are predominant measures of treatment efficacy in Hodgkin lymphoma (HL). Despite preference for OS from many regulatory authorities, PFS is most relevant to patients and frequently serves as primary endpoint in clinical trials. Recently we found a strong correlation between treatment effects on PFS and OS in the first-line setting (Bröckelmann PJ et al. EHA23/ICML23). However, their relationship in the relapsed setting remains unclear. We aimed to evaluate the correlation of PFS with OS after treatment of relapsed HL.

Published
2023
Full Text
View/download PDF

96. Clinical characteristics and outcomes of patients with Hodgkin lymphoma with central nervous system involvement: An international multicenter collaboration

Author

Cheah, Chan Y., primary, Bröckelmann, Paul J., additional, Chihara, Dai, additional, Moskowitz, Alison J., additional, Engert, Andreas, additional, Jerkeman, Mats, additional, El-Galaly, Tarec C., additional, Augustson, Bradley, additional, Vose, Julie, additional, Bartlett, Nancy L., additional, Villa, Diego, additional, Connors, Joseph M., additional, Feldman, Tatyana, additional, Pinnix, Chelsea C., additional, Milgrom, Sarah A., additional, Dabaja, Bouthaina, additional, Oki, Yasuhiro, additional, and Fanale, Michelle A., additional

Published
2016
Full Text
View/download PDF

99. Leucocyte and eosinophil counts predict progression‐free survival in relapsed or refractory classical Hodgkin Lymphoma patients treated with PD1 inhibition.

Author

Hude, Ida, Sasse, Stephanie, Bröckelmann, Paul J., von Tresckow, Bastian, Momotow, Jesko, Engert, Andreas, and Borchmann, Sven

Subjects
PROGRESSION-free survival, HODGKIN'S disease, EOSINOPHILS, LEUCOCYTES, IMMUNE response
Abstract

The article provides information on a study which observed the link between different blood count parameters at baseline with response and progression-free survival (PFS) in relapsed or refractory (r/r) classical Hodgkin lymphoma (cHL) patients treated with the anti-PD1 antibody, nivolumab. Topics discussed include role of eosinophils as co-effectors of the immune response, and results of the study.

Published
2018
Full Text
View/download PDF

100. Real-world effectiveness of brentuximab vedotin versus physicians’ choice chemotherapy in patients with relapsed/refractory Hodgkin lymphoma following autologous stem cell transplantation in the United Kingdom and Germany.

Author

Zagadailov, Erin A., Corman, Shelby, Chirikov, Viktor, Johnson, Courtney, Macahilig, Cynthia, Seal, Brian, Dalal, Mehul R., Bröckelmann, Paul J., and Illidge, Tim

Subjects
DRUG efficacy, CANCER chemotherapy, HODGKIN'S disease, STEM cell transplantation, CANCER relapse, PROGRESSION-free survival, PATIENTS
Abstract

This retrospective study compared effectiveness of (brentuximab vedotin) BV to other chemotherapies in patients with rrHL following an autologous stem cell transplant (ASCT). Data originated from a medical chart review of patients treated in real-world clinical settings at 50 sites in the United Kingdom and Germany. Inverse probability of treatment weights based on propensity scores were used to adjust for differences in baseline characteristics between treatment groups. Among 312 rrHL patients included, 196 received BV and 116 received physicians’ choice chemotherapy. Median PFS was significantly longer (27.0 months vs. 13.4 months; p = .0144) and 12-month OS survival greater (78.1% vs. 65.9%; p = .0129) with BV compared to chemotherapy. Documented adverse events included leukopenia (12.8%) and peripheral neuropathy (8.7%) for BV and leukopenia (12.1%), anemia (5.2%) and diarrhea (5.2%) for chemotherapy. In this real-world study, rrHL patients treated for relapse after ASCT with BV had longer median PFS and 12-month OS than patients receiving chemotherapy. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results